MTOR and hepatocellular carcinoma: Although we have a high number of patients having undergone OLT for autoimmune liver diseases, these patients are rather left on highTAC/mycophenolate, compared with patients transplanted for malignant diseases, such as hepatocellular carcinoma, which gives us reason to discontinue highTAC/mycophenolate and switch to EVR/lowTAC due to the mTOR inhibitors' antiproliferative effects (17–21).